Curevac In Tübingen 02

CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.

At the beginning of the COVID-19 pandemic, CureVac was considered a beacon of hope for the development of a German vaccine. The federal government invested 300 million euros in the company. First, the CureVac vaccine was delayed due to minor problems, while the previously unknown BioNTech developed with Pfizer the very effective BNT162b2. In mid-2021, however, it became clear that the CureVac-vaccine was only 47 percent effective and is far away from approval.

The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations, the International AIDS Vaccine Initiative, and the government of Germany.

History

Research collaborations

In 2007, Curevac received the innovation prize of the state of Baden-Württemberg and was also the winner of the nationwide Weconomy competition, which is jointly awarded by the Handelsblatt and the Wissensfabrik.

In October 2013 CureVac launched a collaboration with Janssen Pharmaceuticals Inc., a Johnson & Johnson company, for the development of novel flu vaccines. Also in 2013, CureVac announced the fourth in a series of partnerships with the Cancer Research Institute and Ludwig Cancer Research to enable clinical testing of novel cancer immunotherapy treatment options.

In March 2014, CureVac won a prize awarded by the European Commission to stimulate new vaccine technologies. Later, in July 2014, CureVac signed an exclusive license agreement with Sanofi Pasteur to develop and commercialize an mRNA-based prophylactic vaccine. By September 2014, the company licensed the global rights for its Phase I candidate – CV9202 – to Boehringer Ingelheim. Boehringer was to conduct trials using the mRNA vaccine in combination with afatinib in advanced and/or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as well as inoperable stage III NSCLC.

In March 2015, a CureVac investor, the Bill & Melinda Gates Foundation, agreed to provide separate funding for several projects to develop prophylactic vaccines based on CureVac's proprietary mRNA platform. By September 2015, CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate the development of AIDS vaccines, utilizing immunogens developed by IAVI and partners, delivered via CureVac's mRNA technology. That same month, CureVac announced it would open a United States hub in Boston, Massachusetts.

In accordance with its deal with Lilly, the company began construction on a production facility in 2016.

In February 2019, the Coalition for Epidemic Preparedness Innovations (CEPI) awarded CureVac a $34 million grant from to develop its proprietary "RNA printer" prototype. The technology is expected to allow the company to rapidly produce mRNA vaccine candidates at scale, from multiple locations globally, to bypass the logistical hurdles that often delay the production of vaccines in response to infectious disease emergencies, and also enable the production of personalized medicines. The initial uses would be for their candidate vaccines for Lassa fever, yellow fever, and rabies.

In July 2020, Tesla, Inc CEO Elon Musk announced via Tweet that Tesla and CureVac had reached an agreement to produce portable "RNA microfactories" based on this technology to manufacture CureVac's COVID-19 vaccine candidate. CureVac had stated that the bioprinters would be able to produce “more than a hundred thousand doses” within approximately two weeks. At approximately the same time, Tesla and CureVac filed a joint patent on the technology. In August, Musk reviewed the project with Curevac while in Germany.

In November 2020, while again visiting German facilities, Musk Tweeted that CureVac was then using a second generation of the technology, and "Version 3 is under development." He said that the platform would be an “important product for the world.”

Investment

By 2017, CureVac had received investments of approximately () in the form of equity and was valued at . In June 2020, the federal government announced that the state-owned development bank KfW would immediately invest 300 million euros in CureVac, which will mean that it will hold a 23 percent stake in CureVac.

On 14 August 2020, CureVac began public trading on the NASDAQ exchange under the ticker symbol, CVAC, raising in its initial public offering.

Reports of Trump administration overtures

On 11 March 2020, it was reported that CureVac AG's CEO Daniel Menichella was no longer the company's CEO, having been replaced by company founder Ingmar Hoerr. Menichella was reported to have met U.S. President Donald Trump on 2 March. According to ''Welt am Sonntag'', quoting an anonymous German government source, Trump had attempted to persuade CureVac to relocate to the United States, a proposal vigorously rejected by German officials. On 16 March, CureVac issued a statement on Twitter, stating "To make it clear again on coronavirus: CureVac has not received from the US government or related entities an offer before, during and since the Task Force meeting in the White House on March 2. CureVac rejects all allegations from press."

COVID-19 vaccine candidate

CVnCoV is an mRNA vaccine that encodes a minimal piece of the coronavirus spike protein, and activates the immune system against it. CVnCoV technology does not interact with the human genome.

In December 2020, CureVac began a Phase III clinical trial of CVnCoV with 36,500 participants. Bayer will provide clinical trial support and international logistics for the Phase III trial, and may be involved in eventual manufacturing should the vaccine prove to be safe and effective. In January 2021, CureVac announced a clinical development collaboration for its COVID-19 vaccine, named ''CVnCoV'' (active ingredient zorecimeran), with the multinational pharmaceutical company Bayer. As of December 2020, CVnCoV was in a Phase III clinical trial of 36,500. On 12 February 2021, CureVac announced the initiation of a rolling submission with the European Medicines Agency (EMA) for their vaccine candidate, a time-optimized process for the review of all data necessary for potential market authorization.
On 16 June 2021, the CureVac announced that phase III-trials of its mRNA-vaccine showed an efficacy of 47%. This falls short of the European Medicines Agency's target efficacy of at least 50%.

Beyond CVnCoV, CureVac has also partnered with GlaxoSmithKline (GSK) to develop a new generation of mRNA-based COVID-19 vaccines. Human testing is due in late 2021.

The start of the phase 1 study with the product candidate CV2CoV, which was announced for the fourth quarter of 2021, had to be postponed to the first quarter of 2022. Since an approval-relevant study for the new vaccine can only be carried out in the fourth quarter of 2022, the goal originally set for mid-October of “obtaining official approval for the marketability of an improved Covid-19 vaccine in 2022” can be achieved in 2023 at the earliest.

References

External links

*

{{authority control

Biopharmaceutical companies
Biotechnology companies of Germany
Cancer organisations based in Germany
Pharmaceutical companies of Germany
Biotechnology companies established in 2000
German companies established in 2000
Pharmaceutical companies established in 2000
Medical and health organisations based in Baden-Württemberg
Companies listed on the Nasdaq
2020 initial public offerings
Tübingen
Vaccine producers
COVID-19 vaccine producers